Activity of two different triazoles in a murine model of paracoccidioidomycosis.
A new orally absorbable triazole (Schering 39304) with a long serum half-life in man (60 hours), was tried in a murine model of progressive paracoccidioidomycosis and compared with itraconazole, another triazole which has proven effective in this mycosis. Only 15% of the infected, untreated mice survived while 53 to 75% of the animals receiving itraconazole survived. Mice treated with Schering 39304 exhibited higher (86-100%) survival rates. Statistically, the 5 mg/kg Sch 39304 was superior to the 50 mg/kg itraconazole dose. Lung cultures showed that 20 mg/kg/day of Sch achieved sterilization of the infectious foci. These results indicate that the new triazole will have a place in the treatment of paracoccidioidomycosis.
Restrepo
S
S
Corporación de Investigaciones Biológicas (CIB), Hospital Pablo Tobón Uribe, Medellin, Colombia.
Tabares
A M
AM
Restrepo
A
A
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D005260:Female; D017964:Itraconazole / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010229:Paracoccidioidomycosis / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D013997:Time Factors; D014230:Triazoles / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; C056513:Sch 39304; D017964:Itraconazole